CAPLYTA (lumateperone)

About Intra-Cellular Therapies

Intra-Cellular Therapies is a commercial-stage biopharma company that transitioned from an independent entity to a subsidiary of Johnson & Johnson, significantly bolstering its resources and commercial reach. The company's core approach is based on pioneering intracellular research, which it applies to develop novel therapeutics for underserved mental health and neurological conditions. Its lead asset, CAPLYTA, is an FDA-approved treatment for schizophrenia and bipolar depression, representing a validated commercial product. The company's integration into J&J provides a powerful platform for lifecycle management of its approved drug and advancement of its broader pipeline.

Therapeutic Areas

Other Schizophrenia, Bipolar Depression Drugs